NCT04311710View on ClinicalTrials.gov

A Study Evaluating the Drug Levels of Iplimumab Given Under the Skin Alone and in Combination With Nivolumab in Multiple Tumor Types

PHASE1TerminatedINTERVENTIONAL
Enrollment

21

Participants

Timeline

Start Date

June 25, 2020

Primary Completion Date

January 14, 2021

Study Completion Date

January 18, 2023

Conditions
Tumor
Interventions
DRUG

ipilimumab

Specified Dose on Specified Days

DRUG

nivolumab

Specified Dose on Specified Days

DRUG

ENHANZE (rHuPH20)

Specified Dose on Specified Days

DRUG

nivolumab

Specified Dose on Specified Days

Trial Locations (6)

1023

Local Institution - 0010, Auckland

20089

Humanitas-U.O di Oncologia medica ed Ematologia, Rozzano

46804

Local Institution - 0013, Fort Wayne

53100

ospedale le scotte-U.O.C. Immunoterapia Oncologica, Siena

80131

Istituto Nazionale Tumori IRCCS Fondazione Pascale-s.c. melanoma, immunoterapia oncologica e terapie, Napoli

06106

Local Institution - 0020, Hartford

Sponsors
All Listed Sponsors
lead

Bristol-Myers Squibb

INDUSTRY

NCT04311710 - A Study Evaluating the Drug Levels of Iplimumab Given Under the Skin Alone and in Combination With Nivolumab in Multiple Tumor Types | Biotech Hunter | Biotech Hunter